Business Description
Nuvation Bio Inc
NAICS : 541713
SIC : 2834
ISIN : US67080N1019
Share Class Description:
NUVB: Ordinary Shares - Class ADescription
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 49.07 | |||||
| Equity-to-Asset | 0.88 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 4.15 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -31.5 | |||||
| 3-Year EPS without NRI Growth Rate | -22.4 | |||||
| 3-Year FCF Growth Rate | -22.8 | |||||
| 3-Year Book Growth Rate | 40.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 65.73 | |||||
| 9-Day RSI | 57.88 | |||||
| 14-Day RSI | 55.36 | |||||
| 6-1 Month Momentum % | -6.67 | |||||
| 12-1 Month Momentum % | 87.92 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 9.57 | |||||
| Quick Ratio | 9.57 | |||||
| Cash Ratio | 9.3 | |||||
| Days Sales Outstanding | 19.33 | |||||
| Days Payable | 627.69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 | |||||
| Shareholder Yield % | -0.45 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | -32.38 | |||||
| Operating Margin % | -25879.56 | |||||
| Net Margin % | -24619.84 | |||||
| FCF Margin % | -4594.26 | |||||
| ROE % | -103.53 | |||||
| ROA % | -87.78 | |||||
| ROIC % | -3137.07 | |||||
| ROC (Joel Greenblatt) % | -14295.14 | |||||
| ROCE % | -97.62 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 313.33 | |||||
| PB Ratio | 1.89 | |||||
| Price-to-Tangible-Book | 1.89 | |||||
| EV-to-EBIT | -0.64 | |||||
| EV-to-Forward-EBIT | -0.12 | |||||
| EV-to-EBITDA | -0.64 | |||||
| EV-to-Revenue | 166.83 | |||||
| EV-to-Forward-Revenue | 249.12 | |||||
| EV-to-FCF | -3.63 | |||||
| Price-to-Net-Current-Asset-Value | 1.91 | |||||
| Price-to-Net-Cash | 1.97 | |||||
| Earnings Yield (Greenblatt) % | -156.25 | |||||
| FCF Yield % | -10.47 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NYSE:NUVB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nuvation Bio Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 2.162 | ||
| EPS (TTM) ($) | -2.18 | ||
| Beta | 0 | ||
| Volatility % | 112.77 | ||
| 14-Day RSI | 55.36 | ||
| 14-Day ATR ($) | 0.180386 | ||
| 20-Day SMA ($) | 2.766 | ||
| 12-1 Month Momentum % | 87.92 | ||
| 52-Week Range ($) | 1.43 - 4.1598 | ||
| Shares Outstanding (Mil) | 336.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nuvation Bio Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nuvation Bio Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nuvation Bio Inc Frequently Asked Questions
What is Nuvation Bio Inc(NUVB)'s stock price today?
The current price of NUVB is $2.82. The 52 week high of NUVB is $4.16 and 52 week low is $1.43.
When is next earnings date of Nuvation Bio Inc(NUVB)?
The next earnings date of Nuvation Bio Inc(NUVB) is 2025-02-28 Est..
Does Nuvation Bio Inc(NUVB) pay dividends? If so, how much?
Nuvation Bio Inc(NUVB) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers